SCIREX Corporation today announced the appointment of Dr. Samer E. Kaba to the position of Vice President Clinical Research and Medical Management.
Horsham, PA, May 2, 2005 -- SCIREX Corporation today announced the appointment of Dr. Samer E. Kaba to the position of Vice President Clinical Research and Medical Management. Dr. Kaba will direct the operations of the Medical Management and Safety group, monitor the medical and safety aspects of projects managed by the company and provide medical and safety consulting services to Sponsors, clinical sites and project teams.
Dr. Kaba joins SCIREX from PRA International, where most recently he was Senior Director, CNS, Global Product Development Services, responsible for formulating clinical development strategies and providing consultative and life cycle management advisory services for new therapies.
Dr. Kaba is a graduate of the Damascus University School of Medicine and did residency training in internal medicine and neurology at the State University of New York (SUNY), Buffalo. He completed fellowships in neuro-immunology/multiple sclerosis at SUNY, and in neuro-oncology at the University of Texas M. D. Anderson Cancer Center in Houston, where he also served as a faculty member. Dr. Kaba currently holds an adjunct faculty position at the Department of Neurology at Emory University in Atlanta. He served as the Director of Research at the Shepherd MS Center in Atlanta and as Assistant Professor at the University of Arkansas in Little Rock, where he also managed a private neurology practice. Dr. Kaba is certified by the American Board of Psychiatry and Neurology and has multiple scientific publications on topics relating to CNS diseases and disorders. He holds professional memberships in the American Academy of Neurology, the Society for Neuro-Oncology, the American Society of Clinical Oncology, and the American Academy of Pharmaceutical Physicians.
"This is a significant appointment for SCIREX," said John Whalen, M.D., General Manager, Clinical Development Services. "Since excellence in clinical trial design and patient safety are at the heart of the services we provide our clients, Dr. Kaba's academic achievements, his experience as a clinician and his substantial industry experience make him superbly qualified to lead these critical areas of our operations."
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.